NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication

EMERYVILLE, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NBY&src=ctag” target=”_blank”gt;$NBYlt;/agt; lt;a href=”https://twitter.com/hashtag/Avenova?src=hash” target=”_blank”gt;#Avenovalt;/agt;–NovaBay®
Pharmaceuticals, Inc.
(NYSE American: NBY), a biopharmaceutical
company focusing on commercializing prescription Avenova® for
the domestic eye care market, announces that it will hold a virtual
Annual Meeting of Stockholders on Thursday, May 30, 2019 at 5:00 p.m.
Pacific time. Registered holders and beneficial stockholders, who
register for the meeting in advance, will be able to participate in the
meeting, vote and submit questions during the meeting via a live webcast
by visiting www.meetingcenter.io/263757134.

The Company also notes that on April 12, 2019 it received notice (the
“Notice”) from the NYSE American LLC that it is not in compliance with
Section 1003(a)(iii) of the NYSE American Company Guide requiring
stockholders’ equity of $6.0 million or more if it has reported losses
from continuing operations and/or net losses in its five most recent
fiscal years. Therefore, the Company has become subject to the
procedures and requirements of Section 1009 of the NYSE American Company
Guide and must submit a plan of compliance by May 12, 2019 addressing
how it intends to regain compliance with Section 1003(a)(iii) of the
NYSE American Company Guide by October 12, 2020. The Notice has no
immediate impact on the listing of the Company’s common stock and does
not affect its ongoing business operations or Securities and Exchange
Commission reporting requirements.

“We continue to have the full support of our majority shareholders, as
recently demonstrated by the consolidation of their holdings,” said
Justin Hall, Interim President and CEO. “It’s gratifying to have their
continued support, and we fully intend to submit a plan to regain
compliance with NYSE American listing standards within the required time
period.”

If the NYSE American accepts the plan, the common stock will continue to
be listed and traded on the NYSE American during that specified period.
If the Company does not regain compliance with NYSE American listing
standards, or does not make progress consistent with the plan, the NYSE
American staff may commence delisting proceedings.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay
Pharmaceuticals, Inc. is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories: the
NEUTROX® family of products and the AGANOCIDE®
compounds. The Neutrox family of products includes AVENOVA®
for the eye care market, NEUTROPHASE® for wound care market,
and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target applications
in the dermatology and urology markets.

Forward-Looking Statements
This release contains
forward-looking statements that are based upon management’s current
expectations, assumptions, estimates, projections and beliefs. These
statements include, but are not limited to, statements regarding our
future listing on the NYSE, our ability to continue as a going concern,
and generally the company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute to
such differences include, but are not limited to, risks and
uncertainties relating to our ability to remain a publicly listed
company, maintain the support of our majority shareholders, and ability
to adhere to our approved NYSE compliance plan. Other risks relating to
NovaBay’s business, including risks that could cause results to differ
materially from those projected in the forward-looking statements in
this press release, are detailed in NovaBay’s latest Form 10-Q/K filings
with the Securities and Exchange Commission, especially under the
heading “Risk Factors.” The forward-looking statements in this release
speak only as of this date, and NovaBay disclaims any intent or
obligation to revise or update publicly any forward-looking statement
except as required by law.

Socialize and Stay informed on NovaBay’s
progress:

Like us on Facebook
Follow
us on 
Twitter
Connect
with NovaBay on 
LinkedIn
Join
us on 
Google+
Visit
NovaBay’s 
Website

Avenova Purchasing Information
For
NovaBay Avenova purchasing information:
Please call 800-890-0329 or
email sales@avenova.com.
www.Avenova.com

Contacts

NovaBay Contact
Justin Hall
Interim
President and Chief Executive Officer
510-899-8800
jhall@novabay.com

Investor Contact
LHA Investor
Relations
Jody Cain
310-691-7100
jcain@lhai.com